4.4 Article

National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing

Related references

Note: Only part of the references are listed.
Article Oncology

Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program

Richard Gorlick et al.

PEDIATRIC BLOOD & CANCER (2009)

Article Oncology

Molecular characterization of the pediatric preclinical testing panel

Geoffrey Neale et al.

CLINICAL CANCER RESEARCH (2008)

Article Oncology

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

John M. Maris et al.

PEDIATRIC BLOOD & CANCER (2008)

Article Oncology

Initial testing of dasatinib by the Pediatric Preclinical Testing Program

E. Anders Kolb et al.

PEDIATRIC BLOOD & CANCER (2008)

Article Oncology

The pediatric preclinical testing program: Description of models and early testing results

Peter J. Houghton et al.

PEDIATRIC BLOOD & CANCER (2007)

Article Oncology

Molecular cytogenetic characterization of rhabdomyosarcoma cell lines

S Rodriguez-Perales et al.

CANCER GENETICS AND CYTOGENETICS (2004)

Article Multidisciplinary Sciences

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

MS Neshat et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Article Multidisciplinary Sciences

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

K Podsypanina et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Article Multidisciplinary Sciences

Short tandem repeat profiling provides an international reference standard for human cell lines

JR Masters et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Article Oncology

Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines

N Keshelava et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)